Observational Advanced Age Study for RMS Patients Treated with Cladribine Tablets
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (≥ 50 years) Treated with Cladribine Tablets
-
Clinical Trial Information
Trial Contact: Carlo, Charlene S; Monserrate, Francheska
Trial Phone: 321.841.1324 ; 321-841-4717
-
IRB No: 22.131.06
Protocol Abbrev: Aging Study
Principal Investigator: Amparo Gutierrez, MD
Age Group: Adult
Secondary Protocol No: MS700568_0185
Treatment: N/A- Observational study
Therapies Involved: Medication
-
Objective
To estimate the annualized relapse rate (ARR) over 24 months after cladribine tablet initiation in a
real world, US cohort of patients with RMS who are aged 50 years or older at the time of cladribine
tablet initiation -
Key Eligibility
Adults aged 50 or older at the start of cladribine tablets, on or before January 2022, with definite RMS or active SPMS
